CAMBRIDGE, UK and NEW YORK, USA, 27 July 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, today announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.
News
Today we confirmed the appointment of our latest partner hires as part of our expansion plans to open in Ireland.
The firm welcomes two new partners to open Taylor Wessing Ireland* with the support of UK partners James Goold and Alison Dennis.
Adam Griffiths, who was previously a member of the firm's private equity group and relocated to Ireland in 2017, has returned to Taylor Wessing to lead operations in Dublin.
Click here to view the July edition of Dates for Your Diary
Alderley Park, Cheshire – Infex Therapeutics is pressing ahead with a major development of its pandemic resilience strategy by today announcing an agreement with CRUK Newcastle Drug Discovery Unit. This will in-licence a novel therapy designed to treat SARS-CoV-2 along with future variants and a broad spectrum of coronaviruses.
The program, PAN-X, is an early stage drug that has shown encouraging activity during in-vitro testing.
- Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
- Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.
- Enables accurate modelling of the human colon and the mucosal barrier
- Provides new insights to the relationship between human microbiome and effect on human health
- Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ microphysiological systems
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Appointment supports international growth within ion channel contract research and drug discovery